Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Berberine as an Antimicrobial Agent and Gut Microbiota Modulator: Mechanisms and Therapeutic Potential.

Current medicinal chemistry·2026
Same author

Detection of cochlear microphonic for differential diagnosis between auditory neuropathy mice and noise-induced sensorineural hearing loss mice.

Journal of neuroscience methods·2026
Same author

Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift.

Frontiers in immunology·2026
Same author

Plasma p-Tau217 and Aβ42/Aβ40 mediate the association between minimal depressive symptoms and cognitive impairment.

Journal of neurology·2026
Same author

In-situ Damascus-patterning enables tunable surface electric fields for bioactive titanium implants.

Bioactive materials·2026
Same author

Non-Optimal Temperatures and Global Disease Burden: Retrospective Analysis of 2010-2021 and Projections to 2040.

Journal of occupational and environmental medicine·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Yuhan Chen1, Zhiqi Mao2

  • 1Hebei North University, Zhangjiakou, Hebei, China.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Reduced levels of LIM-domain-only 4 (LMO4) in cerebrospinal fluid are linked to Alzheimer's disease (AD) progression, neurodegeneration, and cognitive decline. LMO4 may serve as a therapeutic target for AD.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Research
  • Alzheimer's Disease Pathogenesis

Background:

  • LIM-domain-only 4 (LMO4) is known for its roles in neurodevelopment and synaptic plasticity.
  • Its specific involvement in the pathogenesis of Alzheimer's disease (AD) has not been clearly defined.

Purpose of the Study:

  • To investigate the association between cerebrospinal fluid (CSF) LMO4 levels and Alzheimer's disease (AD) biomarkers.
  • To explore the relationship between CSF LMO4 and neuropathology, neurodegeneration, and cognitive function in AD.
  • To assess the diagnostic potential of CSF LMO4 in differentiating AD cases.

Main Methods:

  • Analysis of CSF LMO4 levels in 703 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
  • Evaluation of associations with AD biomarkers (Aβ42, Ptau181, amyloid PET) and postmortem neuropathology.
  • Cross-sectional, longitudinal, receiver operating characteristic, and mediation analyses were performed.

Main Results:

  • Lower CSF LMO4 levels correlated with increased Aβ and tau pathology, brain atrophy, and cognitive decline.
  • CSF LMO4 levels were decreased in participants with abnormal Aβ and cognitive impairment.
  • CSF LMO4 demonstrated partial mediation between Aβ and tau pathology and showed diagnostic ability for AD.

Conclusions:

  • CSF LMO4 plays a significant role in the pathogenesis and progression of Alzheimer's disease.
  • CSF LMO4 may represent a potential therapeutic target for AD treatment.